Governance
Corrections Policy
Released: · Last reviewed:
Errors are corrected openly. When a factual error is confirmed, the page is amended, a dated note describes what changed, and the change history at the foot of the page records it. Pages are not silently rewritten, because a quiet edit removes a reader's ability to know whether what they read last month was accurate.
Key takeaways
- Confirmed factual errors are corrected with a dated, described change rather than a silent edit.
- Every page carries a visible change history recording substantive amendments.
- Changes of method or disclosure that contradict what earlier pages said are logged here too, with what the pages said before.
- Corrections can be submitted by anyone, including the provider or pharmacy concerned.
- Providers receive no special standing — a correction requires evidence, not an objection.
- Disputed claims may be labelled as conflicting while evidence is assessed.
| How to submit | Contact page or provider submissions |
|---|---|
| Evidence required | A primary source or dated first-party document |
| Target response | Assessment within a reasonable period, with the outcome recorded |
| Record | Dated entry in the page's change history |
| Provider standing | Same evidentiary standard as any other submitter |
What counts as a correction rather than a disagreement?
A correction concerns a fact that can be checked: a price, a licence number, a trial result, a date, a policy term. A disagreement concerns interpretation — whether a ranking method is the right one, or whether a conclusion is fairly drawn. Corrections are made on evidence. Disagreements may be noted on the page but do not oblige a change.
What happens when a provider disputes a published figure?
The same thing that happens when anyone does: the submitted evidence is assessed against the recorded capture. If the provider supplies a dated document showing a different price, the record is updated and the change history notes both figures and dates. An objection without evidence does not remove a sourced claim, because that would let the subject of a review edit it.
What does a correction notice contain?
- The date the correction was made.
- What the page previously said.
- What it now says.
- The evidence that prompted the change.
Corrections and changes log
The log below records accepted corrections and changes that reverse what earlier pages said. Accepted corrections are also published in corrections.json.
| Date | Pages | What pages said before | What they say now | Why |
|---|---|---|---|---|
| 2026-11-08 | Provider rankings and methodology pages, and every page carrying a ranking | Methodology v1.0: providers ordered by computed cost only, with no editorial score. NexLife was placed third on committed cost, behind TRYM Health and a program since removed from this site. | Methodology v4.1: a weighted editorial rubric of seven categories (pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10). NexLife is the #1 editorial pick at 94/100; other providers are listed alphabetically and have not yet been scored on v4.1. Price tables remain sorted by price under the price-classification rule, and there NexLife is not the lowest. | A change of editorial method, not the correction of a data error. It is logged because earlier pages stated that rankings carried no editorial score. |
| 2026-11-08 | Governance and disclosure pages (about, ownership and funding, affiliate disclosure, advertising policy, conflicts of interest) | Until September 4, 2026, pages said the site took no money from providers. From September 4 to November 7, 2026, they described the site as independent or independently operated, disclosed NexLife as an affiliate/referral partner, said the relationship could not affect rankings because rankings were computed from prices alone, ranked NexLife third on committed cost, and said no other provider, pharmacy or manufacturer had any financial, affiliate, referral or sponsorship relationship with the publisher. | The site is described as affiliate-supported. The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04), which is also the #1 editorial pick. The full relationship and the legal publisher entity are being confirmed with the publisher. | The earlier descriptions no longer matched the ranking method, and the statement about every other company could not be verified in full. |
| 2026-11-08 | Every page with outbound provider links | NexLife links carried a sponsored link attribute, and pages said the relationship was labelled at every point of use, including relationship boxes on individual pages. | One general disclosure in the footer of every page: “Tirzepatide Editorial is affiliate-supported and may earn a commission when readers enroll through links on this site. Compensation never changes our methodology, rankings or the prices we report.” Every outbound provider link carries rel="nofollow noopener" with UTM parameters (utm_source=tirzepatideeditorial, utm_medium=referral, utm_campaign=editorial, utm_content=page slug). No per-page relationship boxes. | Disclosure model consolidated into a single site-wide statement. |
| 2026-09-04 | /best-tirzepatide-providers/ and every page carrying the committed-vs-month-to-month table | Fridays month-to-month tirzepatide rate shown as $240 | Fridays month-to-month rate shown as $359 (about), as the captured source states; $240 is the annual-plan rate | The captured 2026-07-20 source text reads “About $359 month-to-month; about $240/month on annual plan”. The 2026-07-22 build carried the annual rate in both columns. |
| 2026-09-04 | /providers/nexlife/ | Verdict paragraph stated that mandatory-fee inclusion was not confirmed for NexLife | Verdict paragraph matches the record: the captured source states a recurring price with medication included and no separate membership fee | The record's own classification test on the same page; the paragraph was a template error. |
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Submissions, evidence, review timeline and notices and history, organised around the primary question of tirzepatide corrections policy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Submissions | Covered on this page | Regulatory or policy source |
| Evidence | Covered on this page | Regulatory or policy source |
| Review timeline | Covered on this page | Regulatory or policy source |
| Notices and history | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
Any of the following would change what this page concludes:
- New primary evidence bearing directly on tirzepatide corrections policy.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
How do I report an error?
Through the contact page, with the evidence supporting the correction.
Do you delete pages instead of correcting them?
No. Substantive changes are recorded in the page's change history.
Can a provider have a review removed?
No. Providers can submit evidence, which is assessed on the same standard as any other submission.
What if a claim is disputed but not disproven?
It may be labelled as conflicting while the evidence is assessed.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Shared cost components and disclosures rebuilt from the 2026-09-04 dataset (NexLife September 2026 card re-read live; Yucca Health and a program since removed from this site added; NexLife disclosed as a commercial partner, labelled where it appears). |
| 2026-11-08 | Corrections and changes log added. Entries dated 2026-11-08 record the move from cost-only ordering (methodology v1.0) to the v4.1 weighted rubric with NexLife as the #1 editorial pick (94/100); that earlier pages described the site as independent and ranked NexLife third on committed cost; and the move to a single footer disclosure with rel="nofollow noopener" links. The two 2026-09-04 corrections from corrections.json are shown. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.